Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
Status: Open
- Who can apply
- Nonprofits, small businesses, state, local and tribal governments, tribes, schools and universities, for-profit companies, others.
- Deadline
- Thursday, November 19, 2026 - check the notice for the exact time
- Opened Nov 22, 2024
- Amount
- Not stated by the source
- Official source
- Read and apply at the official source Found on grants.gov
- Requirements
- Documents with the official notice: PAR-25-226-Full-Announcement.html
- Organizations need a SAM.gov ID number (UEI) to apply. Individuals do not.
- Application fee
- We do not read fees from notices; check the official notice. GrantsWindow never charges you.
- Funder
- National Institutes of Health (federal)
- Assistance Listing 93.242
- Last checked
- Checked Nov 15, 2026 at the official source
From the official notice
The purpose of this Notice of Funding Opportunity (NOFO) is to invite applications that bundle independent protocols for phase 1 clinical trials with phase 1b/phase 2a clinical trials to streamline the early-stage evaluation of promising pharmacological interventions for Alzheimer's disease (AD) ...
Topics this may fit (our guess)
minority-serving